JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avalos, M.
Right arrow Articles by Luetje, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avalos, M.
Right arrow Articles by Luetje, C. W.

Vol. 302, Issue 3, 1246-1252, September 2002

Effects of Pyridine Ring Substitutions on Affinity, Efficacy, and Subtype Selectivity of Neuronal Nicotinic Receptor Agonist Epibatidine

Melva Avalos, Michael J. Parker1 , Floyd N. Maddox, F. Ivy Carroll and Charles W. Luetje

Department of Molecular and Cellular Pharmacology, University of Miami School of Medicine, Miami, Florida (M.A., M.J.P., F.N.M, C.W.L.); and Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina (F.I.C.)

2'-Pyridine ring substituted analogs of epibatidine were assessed for equilibrium binding affinity, functional potency, and efficacy at rat neuronal nicotinic receptors expressed in Xenopus oocytes. Binding affinities were determined in membrane homogenates from oocytes expressing alpha 2beta 2, alpha 2beta 4, alpha 3beta 2, alpha 3beta 4, alpha 4beta 2, or alpha 4beta 4. Efficacy (relative to acetylcholine) and potency were measured electrophysiologically with oocytes expressing alpha 3beta 4, alpha 4beta 2, and alpha 4beta 4. Hydroxy, dimethylamino, and trifluoromethanesulfonate analogs had affinities too low for accurate measurement. The bromo analog had affinities 4- to 55-fold greater at beta 2 than at beta 4-containing receptors, modestly greater efficacy at alpha 4beta 4 than at alpha 4beta 2, and 5- to 10-fold greater potency at a4beta 4 than at alpha 3beta 4 or alpha 4beta 2. The fluoro analog displayed affinities 52- to 875-fold greater at beta 2- than at beta 4-containing receptors, efficacy at alpha 4beta 4 receptors 3-fold greater than at alpha 4beta 2 and alpha 3beta 4, and was equipotent at all receptors tested. The norchloro analog showed affinities 114- to 3500-fold greater at beta 2- than at beta 4-containing receptors, 2-fold greater efficacy at alpha 4beta 2 and alpha 4beta 4 than at alpha 3beta 4, and 4- to 5-fold greater potency at alpha 4beta 4 and alpha 3beta 4 than at alpha 4beta 2. The amino analog displayed affinities 10- to 115-fold greater at beta 2- than at beta 4-containing receptors, 3-fold greater efficacy at alpha 3beta 4 than at alpha 4beta 2, and 2- to 4-fold greater potency at alpha 3beta 4 and alpha 4beta 4 than at alpha 4beta 2. Although these compounds displayed a variety of differences in affinity, efficacy, and potency, with one exception (binding affinity and functional potency at alpha 4beta 4 receptors) there were no significant correlations among these properties.


1 Present address: Department of Neuroscience, Duke University, Durham, NC 27710.


0022-3565/02/3023-1246$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
K. B. Mihalak, F. I. Carroll, and C. W. Luetje
Varenicline Is a Partial Agonist at {alpha}4beta2 and a Full Agonist at {alpha}7 Neuronal Nicotinic Receptors
Mol. Pharmacol., September 1, 2006; 70(3): 801 - 805.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. Akk, L. S Milescu, and M. Heckmann
Activation of heteroliganded mouse muscle nicotinic receptors
J. Physiol., April 15, 2005; 564(2): 359 - 376.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. A. Jensen, I. Mikkelsen, B. Frolund, H. Brauner-Osborne, E. Falch, and P. Krogsgaard-Larsen
Carbamoylcholine Homologs: Novel and Potent Agonists at Neuronal Nicotinic Acetylcholine Receptors
Mol. Pharmacol., October 1, 2003; 64(4): 865 - 875.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.